Fda accepts valneva's chikungunya vaccine license application for priority review

Saint - herblain ( france), february 20 , 2 02 3 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today announced that the u.s. food and drug administration (fda) has completed a filing review of its biologics license application for valneva's single-shot chikungunya vaccine candidate vla1553 and has determined that the application is sufficiently complete to permit a substantive review. the review classification is priority.
VALN Ratings Summary
VALN Quant Ranking